IMENA L
IMENA L
Not authorised
- Levamisole
- Oxyclozanide
Product identification
Medicine name:
IMENA L
Active substance:
- Levamisole
- Oxyclozanide
Target species:
-
Cattle
-
Sheep
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Levamisole12.70/milligram(s)1.00millilitre(s)
-
Oxyclozanide30.00/milligram(s)1.00millilitre(s)
Pharmaceutical form:
-
Oral suspension
Withdrawal period by route of administration:
-
Oral use
-
Cattle
-
Meat and offal20day
-
Milkno withdrawal periodEn l’absence de limites maximales de résidus pour le lait, ne pas utiliser chez les femelles
productrices de lait de consommation, en lactation ou en période de tarissement ni chez les futures
reproductrices de lait de consommation dans les deux mois qui précèdent la mise bas.
-
-
Sheep
-
Meat and offal17day
-
Milkno withdrawal periodEn l’absence de limites maximales de résidus pour le lait, ne pas utiliser chez les femelles
productrices de lait de consommation, en lactation ou en période de tarissement ni chez les futures
reproductrices de lait de consommation dans les deux mois qui précèdent la mise bas.
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QP52AE51
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Surrendered
Authorised in:
-
France
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
- Intervet
Marketing authorisation date:
Manufacturing sites for batch release:
- Trirx Segre
Responsible authority:
- French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
- FR/V/8501985 6/1986
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
French (PDF)
Published on: 4/04/2022
